난소암 치료제 시장 예측 : 산업 규모, 점유율, 동향, 기회, 약제 클래스별, 종양 유형별, 유통 채널별, 지역별, 경쟁 구도(2021-2031년)
Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Tumor Type, By Distribution Channel, By Region & Competition, 2021-2031F
상품코드:1901619
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 181 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 난소암 치료제 시장은 2025년 43억 2,000만 달러, 2031년까지 63억 6,000만 달러에 달하고, CAGR은 6.66%를 나타낼 전망입니다.
난소암 치료제는 난소, 난관, 복막의 악성 종양을 치료하기 위해 설계된 백금 기반 화학요법, 폴리(ADP-리보스) 중합효소(PARP) 억제제, 혈관신생 억제제 등 다양한 약리학적 개입을 포함합니다. 이 시장은 주로 난소암의 세계 발생률 증가와 노인 인구 증가에 의해 견인되고 있습니다. 나이는 이 질병의 중요한 위험 요인이기 때문입니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
43억 2,000만 달러
시장 규모 : 2031년
63억 6,000만 달러
CAGR : 2026-2031년
6.66%
가장 빠르게 성장하는 부문
알킬화제
가장 큰 시장
북미
주요 시장 성장 촉진요인
PARP 억제제 및 표적 치료제의 진보는 기존의 화학요법과 비교하여 환자의 치료 성적을 개선하는 정밀한 작용기전을 제공함으로써 난소암의 임상관리를 근본적으로 바꾸고 있습니다. 시장에서 항체 약물 복합체 및 엽산 수용체 α와 같은 특정 바이오마커를 표적으로 하는 유지 요법으로의 큰 전환이 나타납니다.
주요 시장 과제
새로운 표적요법과 면역요법에 따른 고액의 비용은 세계의 난소암 치료제 시장의 성장에 큰 장벽이 되고 있습니다. 이러한 첨단 치료법의 고가격 구조는 심각한 경제적 부담을 가져오고, 의료 보험자는 엄격한 상환 정책을 실시할 수밖에 없으며, 그 결과 환자의 적격성이 인구의 극히 일부에 한정되는 경우가 적지 않습니다.
주요 시장 동향
백금 제형 내성 질환에 대한 새로운 치료법의 개발은 내성 사례를 대량으로 다루는 것이 아니라 다른 조직학적 아형에 초점을 맞추는 동향이 강해지고 있습니다. 이 동향은 RAS/MAPK 경로에 의해 구동되는 희소하고 화학요법 저항성 질환 형태인 저악성도 장액성 난소암(LGSOC)에 대한 표적 억제제의 출현에 의해 현저하게 나타났습니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 난소암 치료제 시장 전망
시장 규모 및 예측
금액별
시장 점유율 및 예측
종양 유형별(상피성 난소암, 난소 저악성도 종양, 생식 세포 종양, 성삭-기질 종양)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2025)
시장 맵
제6장 북미의 난소암 치료제 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 난소암 치료제 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 난소암 치료제 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 난소암 치료제 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카
제10장 남미의 난소암 치료제 시장 전망
시장 규모 및 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
합병 및 인수
제품 출시
최근 동향
제13장 세계의 난소암 치료제 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
AstraZeneca, Plc
GlaxoSmithKline, Plc
Merck & Co.
Clovis Oncology, Inc.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Co.
Eli Lilly and Company
Amgen Inc.
CH Boehringer Sohn Ko. KG
Novartis AG
제16장 전략적 제안
제17장 기업 소개와 면책사항
SHW
영문 목차
영문목차
The Global Ovarian Cancer Drugs Market will grow from USD 4.32 Billion in 2025 to USD 6.36 Billion by 2031 at a 6.66% CAGR. Ovarian cancer drugs encompass a diverse range of pharmacological interventions, including platinum-based chemotherapies, poly (ADP-ribose) polymerase (PARP) inhibitors, and angiogenesis inhibitors, designed to treat malignancies of the ovaries, fallopian tubes, and peritoneum. The market is primarily driven by the increasing global incidence of ovarian cancer and the growing geriatric population, as age constitutes a significant risk factor for the disease.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 4.32 Billion
Market Size 2031
USD 6.36 Billion
CAGR 2026-2031
6.66%
Fastest Growing Segment
Alkylating Agents
Largest Market
North America
Key Market Drivers
Advancements in PARP inhibitors and targeted therapeutics are fundamentally altering the clinical management of ovarian cancer by offering precise mechanisms of action that improve patient outcomes compared to traditional chemotherapy. The market is witnessing a significant shift towards antibody drug conjugates and maintenance therapies that target specific biomarkers like folate receptor alpha. This transition is exemplified by the commercial success of recently approved agents which are rapidly capturing market share.
Key Market Challenges
The prohibitive cost associated with novel targeted therapies and immunotherapies constitutes a substantial impediment to the growth of the global ovarian cancer drugs market. High pricing structures for these advanced regimens lead to significant financial toxicity, forcing healthcare payers to implement stringent reimbursement policies that often restrict patient eligibility to a narrow subset of the population. In many regions, particularly developing economies, the resulting high out-of-pocket expenses effectively place these life-extending treatments out of reach for many individuals.
Key Market Trends
The development of novel therapies for platinum-resistant disease is increasingly focusing on distinct histological subtypes rather than treating resistant cases as a monolithic group. This trend is exemplified by the emergence of targeted inhibitors for low-grade serous ovarian cancer (LGSOC), a rare and chemo-resistant form of the disease driven by the RAS/MAPK pathway. Unlike broad-spectrum chemotherapy or antibody-drug conjugates, these regimens utilize RAF/MEK clamps to disrupt oncogenic signaling in tumors harboring KRAS mutations.
Key Market Players
AstraZeneca, Plc
GlaxoSmithKline, Plc
Merck & Co.
Clovis Oncology, Inc.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Co.
Eli Lilly and Company
Amgen Inc.
C.H. Boehringer Sohn Ko. KG
Novartis AG
Report Scope:
In this report, the Global Ovarian Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Ovarian Cancer Drugs Market, By Tumor Type:
Epithelial Ovarian Cancer
Ovarian Low Malignant Potential Tumor
Germ Cell Tumor
Sex Cord-Stromal Tumor
Ovarian Cancer Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Ovarian Cancer Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Ovarian Cancer Drugs Market.
Available Customizations:
Global Ovarian Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Ovarian Cancer Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Ovarian Cancer Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Tumor Type
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Ovarian Cancer Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Tumor Type
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Ovarian Cancer Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Tumor Type
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Ovarian Cancer Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Tumor Type
6.3.3.2.2. By Distribution Channel
7. Europe Ovarian Cancer Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Tumor Type
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Ovarian Cancer Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Tumor Type
7.3.1.2.2. By Distribution Channel
7.3.2. France Ovarian Cancer Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Tumor Type
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Tumor Type
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Ovarian Cancer Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Tumor Type
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Ovarian Cancer Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Tumor Type
7.3.5.2.2. By Distribution Channel
8. Asia Pacific Ovarian Cancer Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Tumor Type
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Ovarian Cancer Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Tumor Type
8.3.1.2.2. By Distribution Channel
8.3.2. India Ovarian Cancer Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Tumor Type
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Ovarian Cancer Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Tumor Type
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Ovarian Cancer Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Tumor Type
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Ovarian Cancer Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Tumor Type
8.3.5.2.2. By Distribution Channel
9. Middle East & Africa Ovarian Cancer Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Tumor Type
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Ovarian Cancer Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Tumor Type
9.3.1.2.2. By Distribution Channel
9.3.2. UAE Ovarian Cancer Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Tumor Type
9.3.2.2.2. By Distribution Channel
9.3.3. South Africa Ovarian Cancer Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Tumor Type
9.3.3.2.2. By Distribution Channel
10. South America Ovarian Cancer Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Tumor Type
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Ovarian Cancer Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Tumor Type
10.3.1.2.2. By Distribution Channel
10.3.2. Colombia Ovarian Cancer Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Tumor Type
10.3.2.2.2. By Distribution Channel
10.3.3. Argentina Ovarian Cancer Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Tumor Type
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Ovarian Cancer Drugs Market: SWOT Analysis
